新型冠状病毒肺炎合并心血管疾病的临床治疗观察  

Observations on clinical treatment of COVID-19 complicated with cardiovascular disease

作　　者：卢昊阳 卢家忠[2] 韩明锋[2] 吕新才[2] 张标[2] 戎成振[2] 贾蕾蕾 潘强强 马蕾蕾 赵韧[1] Lu Haoyang;Lu Jiazhong;Han Mingfeng;Lvh Xincai;Zhang Biao;Rong Chengzhen;Jia Leilei;Pan Qiangqiang;Ma Leilei;Zhao Ren(Department of Cardiovascular Medicine,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China;Department of Cardiovascular Medicine,Fuyang Second People′s Hospital,Fuyang 236000,China)

机构地区：[1]安徽医科大学第一附属医院心血管内科,安徽合肥230022 [2]阜阳市第二人民医院心血管内科,安徽阜阳236000

出　　处：《临床荟萃》2021年第3期203-207,共5页Clinical Focus

基　　金：阜阳市“新型冠状病毒肺炎”科研课题立项项目——新型冠状病毒肺炎患者临床特征分析及相关心脏损伤的探讨(FY2020xg03);安徽省高校自然基金重点项目——TRPP2蛋白在盐敏感性高血压大鼠血压调节中的机制(KJ2014A122)。

摘　　要：目的探讨新型冠状病毒肺炎(COVID-19)合并心血管疾病患者治疗措施。方法收集155例COVID-19患者临床资料,分析155例患者治疗用药情况,并对21例合并心血管疾病患者临床治疗进行分析。结果COVID-19合并心血管疾病单中心发病率13.5%,其中高血压患者较多(95.2%),老年COVID-19患者合并心血管疾病发生率高(38.5%),住院期间急性心血管事件发生率4.76%,在肺炎药物治疗过程中常规心血管病药物应用未见药物不良反应。危重型COVID-19患者住院期间心血管事件发生率高且血浆置换治疗过程中发现1例血压下降,经过扩容升压治疗后改善。未合并心血管疾病134例,在肺炎治疗过程中发现有2例血压升高。结论治疗COVID-19要注意潜在引起的不良反应,普通型COVID-19合并心血管疾病患者治疗常规用药和治疗基本安全有效,对于危重症患者炎症风暴与心血管系统基础疾病可能存在交互影响。Objective To explore the treatment measures for patients suffering from novel coronavirus pneumonia disease(hereinafter referred to as“COVID-19”)with cardiovascular complications.Methods Clinical data of 155 patients with COVID-19 were collected,therapies and medications of such patients were analyzed,and clinical therapies for 21 patients with cardiovascular complications were analyzed.Results The single-center incidence of patients with COVID-19 complicated with cardiovascular complications hit 13.5%,the number of patients with hypertension was greater(95.2%),elderly patients with COVID-19 had higher incidence of complicating cardiovascular diseases(38.5%),incidence of acute cardiovascular events during hospital stay was 4.76%.No adverse drug reactions were observed in the application of conventional cardiovascular drugs during the treatment.Critically type COVID-19 patients had high incidence of cardiovascular events during the hospital stay,one case was found to suffer from the drop of blood pressure in the course of plasma exchange therapy.The symptom was relieved by elevated blood pressure treatment,134 patients who had no cardiovascular complications,two patients experienced hvpertension during the process of pneumonia treatment.Conclusion Potentially induced adverse events should be noted while treating COVID-19 patients.While generic medications and therapies are known to be basically safe and effective for common type of COVID-19 patients with cardiovascular complications,the interactions may potentially take place in critically ill patients with inflammatory cytokine storm and underlying cardiovascular conditions.

关 键 词：新型冠状病毒肺炎 心血管疾病 药物疗法 药物不良反应 

分 类 号：R521.99[医药卫生—内科学]